Research programme: autoimmune disorder therapies - Anaphore/Tanabe Research LaboratoriesAlternative Names: Atrimers for autoimmune disorders - Anaphore/Mitsubishi Tanabe Pharma; Trivalent proteins for autoimmune disorders - Anaphore/Tanabe Research Labs
Latest Information Update: 16 Jul 2016
At a glance
- Originator Anaphore; Tanabe Research Laboratories USA
- Developer Bird Rock Bio; Tanabe Research Laboratories USA
- Class Proteins
- Mechanism of Action Protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 13 Dec 2010 Early research in Autoimmune disorders in USA (unspecified route)